List of clinical studies of menopausal hormone therapy
(Redirected from List of notable clinical studies of menopausal hormone therapy)
The following is a list of notable clinical studies of menopausal hormone therapy (estrogen and/or progestogen therapy) in women, including randomized controlled trials and observational studies.[1][2][3][4][5][6][7]
Randomized controlled trials
[edit]- Clinical Study on Hormone Dose Optimisation in Climacteric Symptoms Evaluation (CHOICE)
- Comparative Effect on Bone Density, Endometrium, and Lipids of Continuous Hormones as Replacement Therapy (CHART)[8]
- Danish Osteoporosis Prevention Study (DOPS) (open-label)
- Early versus Late Intervention Trial with Estradiol (ELITE)
- Estrogen in Prevention of Atherosclerosis Trial (EPAT)
- Estrogen Replacement and Atherosclerosis (ERA)
- Estrogen in Venous Thromboembolism Trial (EVTET)
- Heart and Estrogen/Progestin Replacement Study (HERS)
- Hormone replacement therapy After Breast cancer — Is iT Safe? (HABITS)[9][10]
- Kronos Early Estrogen Prevention Study (KEEPS)
- Papworth HRT Atherosclerosis Study (PHASE)
- Perimenopausal Estrogen Replacement Therapy Study (PERT)[11][12][13]
- Postmenopausal Estrogen/Progestin Interventions (PEPI)
- Stockholm Trial or Stockholm Randomized Trial[14][15][10]
- Women's Estrogen for Stroke Trial (WEST)
- Women's Estrogen Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)
- Women's Health Initiative Estrogen Study (WHI-E)
- Women's Health Initiative Estrogen + Progestin Study (WHI-EP)
- Women's Health, Osteoporosis, Progestin, Estrogen (Women's HOPE)
- Women's International Study of Long-Duration Oestrogen After Menopause (WISDOM)
Observational studies
[edit]- CECILE (French study)
- Combined Cohorts of Menopausal Women, studies of Register Based Health Outcomes in Relation to Hormonal Drugs (COMPREHEND)
- Estrogen and Thromboembolism Risk (ESTHER)
- European Prospective Investigation into Cancer and Nutrition (EPIC)
- French cohort: Etude Epidémiologique auprès de femmes de l'Education National (E3N, E3N-EPIC)
- Framingham Heart Study (FHS)
- Menopause, Estrogen and Venous Events (MEVE)[16]
- Menopause: Risk of Breast Cancer, Morbidity and Prevalence (MISSION)
- Million Women Study (MWS)
- Nurses' Health Study (NHS)
- Study of NorpregnAnes on Coagulation (SNAC)
- Women's Health Initiative Observational Study (WHI-OS)
See also
[edit]References
[edit]- ^ Sayegh, Raja; Awwad, Johnny T. (2017). "Five Decades of Hormone Therapy Research: The Long, the Short, and the Inconclusive". Essentials of Menopause Management. pp. 13–43. doi:10.1007/978-3-319-42451-4_2. ISBN 978-3-319-42449-1.
- ^ Pickar JH, Archer DF, Kagan R, Pinkerton JV, Taylor HS (August 2017). "Safety and benefit considerations for menopausal hormone therapy". Expert Opinion on Drug Safety. 16 (8): 941–954. doi:10.1080/14740338.2017.1343298. PMID 28664754. S2CID 24155838.
- ^ Lobo RA (April 2017). "Hormone-replacement therapy: current thinking". Nature Reviews Endocrinology. 13 (4): 220–231. doi:10.1038/nrendo.2016.164. PMID 27716751. S2CID 2055531.
- ^ Cutchins A, Wenger NK (December 2013). "Is There a Role for Menopausal Hormone Therapy (MHT) for Cardiovascular Disease Prevention in Select Postmenopausal Women?". Current Treatment Options in Cardiovascular Medicine. 15 (6): 722–34. doi:10.1007/s11936-013-0256-3. PMID 23861019. S2CID 2445210.
- ^ Cagnacci A, Venier M (September 2019). "The Controversial History of Hormone Replacement Therapy". Medicina. 55 (9): 602. doi:10.3390/medicina55090602. PMC 6780820. PMID 31540401.
- ^ Cobin RH, Goodman NF (July 2017). "American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause - 2017 Update". Endocrine Practice. 23 (7): 869–880. doi:10.4158/EP171828.PS. PMID 28703650.
- ^ Baber R, Hickey M, Kwik M (2005). "Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations". Drug Saf. 28 (12): 1085–100. doi:10.2165/00002018-200528120-00004. PMID 16329712. S2CID 37014671.
- ^ Speroff L, Rowan J, Symons J, Genant H, Wilborn W (November 1996). "The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial". JAMA. 276 (17): 1397–403. doi:10.1001/jama.1996.03540170041030. PMID 8892714.
- ^ Holmberg L, Anderson H (February 2004). "HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped". Lancet. 363 (9407): 453–5. doi:10.1016/S0140-6736(04)15493-7. PMID 14962527.
- ^ a b Mueck AO, Rabe T, Kiesel L, Strowitzki T (October 2007). "The use of hormone replacement therapy in patients after breast cancer". Minerva Ginecol. 59 (5): 529–41. PMID 17912179.
- ^ Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS (February 2018). "Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial". JAMA Psychiatry. 75 (2): 149–157. doi:10.1001/jamapsychiatry.2017.3998. PMC 5838629. PMID 29322164.
- ^ Geiger PJ, Eisenlohr-Moul T, Gordon JL, Rubinow DR, Girdler SS (November 2019). "Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms". Menopause. 26 (11): 1318–1323. doi:10.1097/GME.0000000000001398. PMC 8294069. PMID 31688579.
- ^ Gordon JL, Rubinow DR, Watkins L, Hinderliter AL, Caughey MC, Girdler SS (May 2020). "The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease". J Clin Endocrinol Metab. 105 (5). doi:10.1210/clinem/dgz262. PMC 7096310. PMID 31838497.
- ^ von Schoultz E, Rutqvist LE (April 2005). "Menopausal hormone therapy after breast cancer: the Stockholm randomized trial". J Natl Cancer Inst. 97 (7): 533–5. doi:10.1093/jnci/dji071. PMID 15812079.
- ^ Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E (January 2013). "Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial". Eur J Cancer. 49 (1): 52–9. doi:10.1016/j.ejca.2012.07.003. PMID 22892060.
- ^ Olié V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY (May 2011). "Hormone therapy and recurrence of venous thromboembolism among postmenopausal women". Menopause. 18 (5): 488–93. doi:10.1097/gme.0b013e3181f9f7c3. PMID 21178641.